Hepatitis delta infection among persons living with HIV in Europe
Liver International · 2023-04 · 43 (4) · 819-828
DOI: 10.1111/liv.15519 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, online erschienen am 21.01.2023. Verfasst von Charles Béguelin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Hepatitis B, Carcinoma, Hepatocellular, Coinfection, Drug Users. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Janssen Scientific Affairs, Janssen Research and Development, Merck Sharp and Dohme.
Abstract (Originalsprache)
Background and Aims A high prevalence of hepatitis delta virus (HDV) infection, the most severe form of viral hepatitis, has been reported among persons living with HIV (PLWH) in Europe. We analysed data from a large HIV cohort collaboration to characterize HDV epidemiological trends across Europe, as well as its impact on clinical outcomes.
Methods
All PLWH with a positive hepatitis B surface antigen (HBsAg) in the Swiss HIV Cohort Study and EuroSIDA between 1988 and 2019 were tested for anti‐HDV antibodies and, if positive, for HDV RNA. Demographic and clinical characteristics at initiation of antiretroviral therapy were compared between HDV‐positive and HDV‐negative individuals using descriptive statistics. The associations between HDV infection and overall mortality, liver‐related mortality as well as hepatocellular carcinoma (HCC) were assessed using cumulative incidence plots and cause‐specific multivariable Cox regression.
Results
Of 2793 HBsAg‐positive participants, 1556 (56%) had stored serum available and were included. The prevalence of HDV coinfection was 15.2% (237/1556, 95% confidence interval [CI]: 13.5%–17.1%) and 66% (132/200) of HDV‐positive individuals had active HDV replication. Among persons who inject drugs (PWID), the prevalence of HDV coinfection was 50.5% (182/360, 95% CI: 45.3%–55.7%), with similar estimates across Europe, compared to 4.7% (52/1109, 95% CI: 3.5%–5.9%) among other participants. During a median follow‐up of 10.8 years (interquartile range 5.6–17.8), 82 (34.6%) HDV‐positive and 265 (20.1%) HDV‐negative individuals died. 41.5% (34/82) of deaths were liver‐related in HDV‐positive individuals compared to 17.7% (47/265) in HDV‐negative individuals. HDV infection was associated with overall mortality (adjusted hazard ratio 1.6; 95% CI 1.2–2.1), liver‐related death (2.9, 1.6–5.0) and HCC (6.3, 2.5–16.0).
Conclusion
We found a very high prevalence of hepatitis delta among PWID across Europe. Among PLWH who do not inject drugs, the prevalence was similar to that reported from populations without HIV. HDV coinfection was associated with liver‐related mortality and HCC incidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.
- Stichting HIV Monitoring, Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
- Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
- Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.
- Institute for Infectious Diseases, Faculty of Medicine, University of Bern, Bern, Switzerland.
- Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
ORCID-Profile: Charles Béguelin, Anders Boyd, Gilles Wandeler
Förderung
- Janssen Scientific Affairs
- Janssen Research and Development
- Merck Sharp and Dohme
- Gilead Sciences
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Zitieren
APA
Béguelin, C., Atkinson, A., Boyd, A., Falconer, K., Kirkby, N., Suter-Riniker, F., Günthard, H. F., Rockstroh, J. K., Mocroft, A., Rauch, A., Peters, L., Wandeler, G., & for EuroSIDA and SHCS (2023). Hepatitis delta infection among persons living with HIV in Europe. Liver International, 43(4), 819-828. https://doi.org/10.1111/liv.15519
Vancouver
Béguelin C, Atkinson A, Boyd A, Falconer K, Kirkby N, Suter-Riniker F, et al. Hepatitis delta infection among persons living with HIV in Europe. Liver International. 2023;43(4):819-828. doi:10.1111/liv.15519
BibTeX
@article{Bguelin2023,
author = {Béguelin, Charles and Atkinson, Andrew and Boyd, Anders and Falconer, Karolin and Kirkby, Nikolai and Suter-Riniker, Franziska and Günthard, Huldrych F and Rockstroh, Jürgen K and Mocroft, Amanda and Rauch, Andri and Peters, Lars and Wandeler, Gilles and for EuroSIDA and SHCS, for EuroSIDA and SHCS},
title = {Hepatitis delta infection among persons living with HIV in Europe},
journal = {Liver International},
year = {2023},
volume = {43},
number = {4},
pages = {819--828},
doi = {10.1111/liv.15519}
}
EUVIMED